12:00 AM
Aug 13, 2012
 |  BC Week In Review  |  Company News  |  Sales & Marketing

XenoPort, Astellas sales and marketing update

In July, Astellas launched Regnite gabapentin enacarbil extended-release tablets in Japan to treat moderate to severe restless less syndrome (RLS). The National Health Insurance (NHI) list price...

Read the full 123 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >